Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era

Nabil F. Saba, Pooja Vijayvargiya, Jan B. Vermorken, Juan P. Rodrigo Tapia, Stefan M. Willems, Nina Zidar, Remco de Bree, Antti Mäkitie, Greg T. Wolf, Athanassios Argiris, Yong Teng, Alfio Ferlito

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.

Original languageEnglish (US)
Article number1202
JournalCancers
Volume14
Issue number5
DOIs
StatePublished - Mar 1 2022
Externally publishedYes

Keywords

  • Angiogenesis
  • Immunotherapy
  • SCCHN
  • Tumor microenvironment
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era'. Together they form a unique fingerprint.

Cite this